Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Corcept Therapeutics (CORT) · oqro.io/stocks/CORT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Corcept Therapeutics insider trading
Have Corcept Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Corcept Therapeutics was filed in the last 90 days. The latest on record was on Mar 20, 2026.
How often do Corcept Therapeutics insiders buy and sell shares?
Since 2005, Corcept Therapeutics insiders reported 352 open-market purchases and 642 sales on Forms 4 and 5, with purchases in 16 different years, most recently 2026.
Who is selling Corcept Therapeutics stock?
In the last 90 days, 7 insiders of Corcept Therapeutics (CORT) reported 41 open-market sales worth $28.5M in total on SEC Form 4. The largest seller by value was Sean Maduck, with $9.65M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade CORT?
No trade in Corcept Therapeutics (CORT) was disclosed by a member of Congress in the last 12 months.
When does Corcept Therapeutics report its next results?
Corcept Therapeutics's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
CORT price and disclosed activity
−15.2% (−$11.43) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $75.05 on Nov 20, 2025 to $63.62 on Nov 20, 2026 (−15.2%). Disclosed in this range: 7 insider trades, 107 pre-arranged insider sales, 0 Congress trades, and 13 13F position changes for 4 quarters ending in it.
$20$40$80$100$120$140$63.62
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 114 trades in this range as a list
James N Wilson, Director · 4 pre-arranged insider sales, about $727Ktraded Nov 13, 2026, filed Nov 17, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Redwood City, California.
Last 12 months
−14.6%
S&P 500 +8.0% over the same dates
Market value
$7.11B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 9.13M shares sold short (8.3% of shares outstanding), +6.3% vs the previous count, 8.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$340M
+64.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$195M
This quarter $142M, a year earlier $54.5M
Net debt
—
Debt —, cash $98.7M, at Sep 30, 2026
Net income, last 12 months
$162M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2005
Insiders of Corcept Therapeutics reported 352 open-market purchases and 642 sales since 2005; purchases in 16 different years, most recently 2026.
Year
Bought
Sold
2026
$3.31M2×2 trades
$91.3M105×105 trades
2025
—
$91.2M107×107 trades
2024
—
$9.76M36×36 trades
2023
—
$7.33M33×33 trades
2022
—
$16.1M20×20 trades
2021
$3.23M2×2 trades
$10.4M21×21 trades
2020
$1.44M13×13 trades
$1.37M5×5 trades
2019
$1.14M2×2 trades
$705K2×2 trades
2018
$8.04M15×15 trades
$7.61M15×15 trades
2017
$55K1×1 trade
$39.2M20×20 trades
2016
$488K3×3 trades
$24.7M42×42 trades
2015
—
$17M49×49 trades
2014
$1.22M9×9 trades
$6.19M24×24 trades
2013
$20K2×2 trades
—
2012
$927K13×13 trades
$421K9×9 trades
2011
$5.85M2×2 trades
$1.98M41×41 trades
2010
$305K3×3 trades
—
2009
$25.1M57×57 trades
$16.2M19×19 trades
2008
$42.5M58×58 trades
—
2007
$30.8M142×142 trades
—
2006
$4.55M28×28 trades
$524K93×93 trades
2005
—
$4.2K1×1 trade
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Nov 13, 2026
Insiders In the 30 days to Nov 13, 2026, insiders filed 0 open-market purchases and 8 open-market sales, about $3.87M, in 3 filings by 3 people. Corcept Therapeutics on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
On the public record for Corcept Therapeutics over the 12 months to Nov 20, 2026: 6 clinical trials.
Late-stage clinical trials
1 active phase 3 trial and 5 active phase 2 trials led by this company, mostly in ovarian neoplasm, ovarian cancer, neoplasms. The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Red flags in its filings
Sep 23
Top officer leaving
“On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Corcept Therapeutics filed 2 open-market purchases (about $3.31M, in 1 filing, by 1 person) and 112 open-market sales (about $98.8M, in 52 filings, by 11 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 103 open-market sales (about $84M, in 63 filings). (Corcept Therapeutics on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 5 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 6 studys sponsored by the company updated in the period; the latest, "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome" (Phase 2, status active not recruiting), was updated on Nov 3, 2026, with primary completion listed for 2026-12. FINRA short interest for CORT on the settlement date of Oct 30, 2026 was 9,125,717 shares (+6.26% on the previous report), about 8.1 days of average volume.
Company reports, price and press. Corcept Therapeutics filed a Form 8-K on Nov 3, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors. Corcept Therapeutics filed a Form 8-K on Sep 23, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
Who holds it. 419 funds reported a stake in Corcept Therapeutics in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (15.1% of the value reported), INGALLS & SNYDER LLC (9.7% of the value reported), RENAISSANCE TECHNOLOGIES LLC (6.4% of the value reported).
Attention. The English Wikipedia article on Corcept Therapeutics was read about 13 times a day in the 7 days to Nov 18, 2026, against a usual 14 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Corcept Therapeutics filed 2 open-market purchases (about $3.31M, in 1 filing, by 1 person) and 112 open-market sales (about $98.8M, in 52 filings, by 11 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 103 open-market sales (about $84M, in 63 filings).
The largest purchase: G Leonard Jr Baker, Director, about $2.5M, filed Mar 20, 2026.
The largest sale: David L Mahoney, Director, about $10.8M, filed Aug 21, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 5 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 6 studys sponsored by the company updated in the period; the latest, "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome" (Phase 2, status active not recruiting), was updated on Nov 3, 2026, with primary completion listed for 2026-12.
FINRA short interest for CORT on the settlement date of Oct 30, 2026 was 9,125,717 shares (+6.26% on the previous report), about 8.1 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 210,578 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $15.3M for its principal executive officer, and an average of $6.27M for the other named executive officers.
Company reports, price and press
Corcept Therapeutics filed a Form 8-K on Nov 3, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Corcept Therapeutics filed a Form 8-K on Sep 23, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the 'Company') of his decision to resign effective as of October 1, 2026."
Corcept Therapeutics filed a Form 8-K on May 28, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "On May 21, 2026, Corcept Therapeutics Incorporated (the 'Company') held its 2026 Annual Meeting of Stockholders (the 'Annual Meeting')."
Press coverage listed by Finnhub: "What Is Driving The Move In Corcept Therapeutics Stock?" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "Can You Justify Buying Corcept Stock Today?" (Yahoo, Nov 6, 2026).
Press coverage listed by Finnhub: "Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary" (Yahoo, Nov 5, 2026).
CORT closed at $67.79 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $112.10 to $67.79, a change of −39.5%.
Who holds it
419 funds reported a stake in Corcept Therapeutics in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (15.1% of the value reported), INGALLS & SNYDER LLC (9.7% of the value reported), RENAISSANCE TECHNOLOGIES LLC (6.4% of the value reported).
Attention
The English Wikipedia article on Corcept Therapeutics was read about 13 times a day in the 7 days to Nov 18, 2026, against a usual 14 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
People read Corcept Therapeutics's Wikipedia article about 14 times a day over the last week, close to the 15 on a usual day of the three months before.
May 15, 2026Busiest day: 54 views on Jun 1, 2026Nov 20, 2026
Views of the article Corcept Therapeutics, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 3, 2026. Quarterly reports are not audited. Read the filing
By product or service
Hypercortisolism Products$249M73%
+20% on the same quarter a year earlier ($208M)
Lifyorli$91.4M27%
$0 the same quarter a year earlier
Total revenue$340M+64%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Overview”, in the company's words
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym in the United States for the treatment of patients suffering from hypercortisolism (also known as “Cushing’s syndrome”). In June 2024, we made an authorized generic version of Korlym available. Our portfolio of proprietary selective cortisol modulators consists of four structurally distinct series totaling more than 1,000 compounds.
What the section covers (12 headings)
Overview
Hypercortisolism (Cushing’s syndrome)
Oncology
Metabolic Diseases
Development of Other Selective Cortisol Modulators
Inflation Reduction Act of 2022
Results of Operations
Liquidity and Capital Resources
Net Operating Loss Carryforwards
Critical Accounting Policies and Estimates
Net Product Revenue
Government Rebates
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026 and Form 10-Q filed Nov 3, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 26, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Interim results from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
Legal proceedings (Item 3)
Purported Securities Class Action: On February 20, 2026, a purported securities class action complaint was filed in the U.S. District Court for the Northern District of California by the Allegheny County Employees’ Retirement System (Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, et al., Case No. 3:26-cv-1525).
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fails to deliver: 18K shares (about $1.58M) were not delivered on time for settlement on Oct 26, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 42.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.2% on ATS, 15.4% with other brokers), above its 26-week average of 39.7%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (13.0%), SIGMA X2 (12.1%), INTELLIGENT CROSS LLC (11.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
When insiders usually buy
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
95%
36 of 38 insider purchases since 2016 came within 30 days after a results announcement
From Corcept Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Corcept Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.